Probiotic-based therapy for cancer: Probiotic Lactobacillus rhamnosus inhibits the expression of mTORC1 and its downstream target AMD1, dismantles mTORC1-AMD1 signaling network, decreases polyamine levels, and inhibits prostate cancer progression via upregulation of its target gene, 1/November/2018, 11.39 pm

Probiotic-based therapy targeting cancer stem cells in Myeloid leukaemia (ML): Probiotic Lactobacillus rhamnosus inhibits cytosolic aminotransferase BCAT1 expression, increases a-ketoglutarate levels, promotes degradation of HIF1a levels, increases DNA demethylase levels, promotes hypomethylation, increases the expression of tumor suppressor genes, inhibits leukaemia-initiating potential of AML cells, promotes differentiation of AML cells, and inhibits cancer progression in AML via up-regulation of its target gene, 11/November/2018, 11.13 pm
November 1, 2018
Probiotic-based anti-cancer therapy for glioblastoma: Probiotic Lactobacillus rhamnosus inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down regulation of its target gene, 1/November/2018, 11.53 pm
November 1, 2018
Show all

Introduction: What they say:

A study from CIC bioGUNE (Center for Cooperative Research in Biosciences), Bizkaia Technology Park, 801 Building, 48160 Derio, Spain shows that “mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.” This study was published, in the 28 June 2017 issue of the journal “Nature” [One of the best journals in General Science with an I.F of 43], by Profs.Carracedo A, Amaia Zabala-Letona, and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Probiotic-based therapy for cancer: Probiotic Lactobacillus rhamnosus inhibits the expression of mTORC1 and its downstream target AMD1, dismantles mTORC1-AMD1 signaling network, decreases polyamine levels, and inhibits prostate cancer progression via upregulation of its target gene


From Significance of the study to Public health relevance:

Given that: (i) prostate cancer is one of the most common form of disease in men; and about 1 in 8 will get it in their lifetime; (ii) each year nearly 14 million people are diagnosed with cancer globally; (iii) each year 176,000 cases of prostate cancer are identified in the US and about 28,000 of them will die, while in the UK each year 47,000 cases are identified and about one fourth of them will die; (iv) about 70% of Prostate cancers are deficient in tumor suppressor gene PTEN, the second most mutated gene in cancer, the first being tumor suppressor Tp53; (v) cancer deaths globally are expected to be doubled in the next decade; (vi) metastasis is the principle reason for most of the cancer deaths; (vii) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) activate patients’ immune system against tumors (Cancer immunotherapy); (ii) anti-cancer drugs that target cancer stem cells that aid in tumor relapse and resistance; (iii) anti-cancer drugs that target cell adhesion molecules that aid in metastatic spread; (iv) a cheaper alternative to the existing expensive anticancer drugs; (v) a side-effect-free natural product-based drug; (vi) increase the therapeutic index of anti-cancer drugs; and (vii) a way to effectively treat and prevent metastatic progression and relapse of advanced/drug-resistant cancers.


What we infer from what they say:

Prof. Carracedo’s research team has recently shown that:(1) S-adenosylmethionine decarboxylase 1 (AMD1) is highly expressed in prostate cancers with activated mTORC1; (2) mTORC1-activated signals stabilize AMD1; (3) decarboxylated S-adenosylmethionine and polyamine levels are increased in a mouse model and human biopsies of prostate cancer; and (4) mTORC1 inhibitor everolimus: a) decreases the expression of AMD1 and the production of decarboxylated S-adenosylmethionine and polyamines; and b) inhibits proliferation, suggesting that inhibition of the components of the mTORC1-AMD1 signalling may stall prostate cancer progression.


From research findings to therapeutic opportunity :

Probiotic Lactobacillus rhamnosus has been shown to function as an anti-cancer agent. However, the detailed mechanism of action is yet to emerge.

Figure 1. Mechanistic insights into how Lactobacillus rhamnosus decreases the levels of mTORC1 and its downstream target AMD1 to stall prostate cancer metastasis

Figure 2.Probiotic Lactobacillus rhamnosus functions as an anticancer agent through downregulation of AMD1.

This study suggests, for the first time that, Probiotic Lactobacillus rhamnosus, by increasing the expression of its target genes, it may decrease the expression of mTORC1 (fig. 1). Thereby, it may: (i) decrease the stability and levels of AMD1; (ii) decrease decarboxylated S-adenosylmethionine and polyamine levels; (iii) inhibit prostate cancer proliferation; (v) reduce metastasis; and (vi) promote survival (Fig.1).

Thus, pharmacological formulations encompassing “Probiotic Lactobacillus rhamnosus, either alone or in combination with other known anticancer drugs” may be used to inhibit metastatic progression of prostate cancers.


Details of the Research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How does probiotic Lactobacillus rhamnosus decrease the levels of MTORC1 and AMD1 ?

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

#Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L.,  Probiotic-based therapy for cancer: Probiotic Lactobacillus rhamnosus inhibits the expression of mTORC1 and its downstream target AMD1, dismantles mTORC1-AMD1 signaling network, decreases polyamine levels, and inhibits prostate cancer progression via upregulation of its target gene, 1/November/2018, 11.38 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, Kindly drop us a line at admin@genomediscovery.org

Comments are closed.